OVARIAN CANCER and US: Trastuzamab

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label Trastuzamab. Show all posts
Showing posts with label Trastuzamab. Show all posts

Saturday, March 27, 2010

full access: Trastuzumab (Herceptin) sensitizes ovarian cancer cells to EGFR-targeted therapeutics



In research:

Background:  Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and late stage breast cancer. However, clinical studies of trastuzumab in epithelial ovarian cancer (EOC) patients have not met the same level of success. Surprisingly, however, no reports have examined either the basis for primary trastuzumab resistance in ovarian cancer or potential ways of salvaging trastuzumab as a potential ovarian cancer therapeutic.